arrow
C

Charlotte Manisty

university college london
H指数:61
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial

从HER2治疗相关心脏功能不全恢复后停用药物治疗的安全性:HER-SAFE试验

2026-08-300
OAAI
Machine learning—enhanced baseline risk prediction models for cancer therapy related cardiac dysfunction: a systematic review and critical appraisal of methodological quality

机器学习增强的癌症治疗相关心脏功能障碍基线风险预测模型:方法学质量系统评价与批判性评估

2026-08-100
OAAI
Prevalence and determinants of asymmetric septal hypertrophy (ASH) in diseases of left ventricular hypertrophy (LVH)

左心室肥厚(LVH)疾病中非对称室间隔肥厚(ASH)的患病率及其影响因素

2026-08-030
OAAI
Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders – The EXCALIBUR study

利用植入式环状记录仪探索心脏淀粉样变性中的心律失常负担——EXCALIBUR研究

JACC
IF0
2026-05-100
OAAI
Reappraising cardiac function with myocardial contraction fraction: normal values, disease detection, and prognostication

Kurdi, H.; Thornton, G.; Shiwani, H.; Artico, J.; Abiodun, A.; Castelletti, S.; Rosmini, S.; Nordin, S.; Augusto, J.; Kozor, R.; et al. 重新评估心脏功能:心肌收缩分数的临床应用价值——正常值、疾病检测与预后判断。Eur. Heart J. Cardiovasc. Imaging 2026, 27, 803–816. [Google Scholar] [CrossRef]

2026-04-010
PRE
SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk

SHP2:连接免疫检查点抑制剂疗法、癌症治疗与血管风险的氧化还原敏感性调节因子

2025-11-210
OAAI
Myocardial Amyloid Burden in Transthyretin Amyloidosis

转甲状腺素蛋白淀粉样变性中的心肌淀粉样蛋白负荷

JACC
IF0
2025-11-080
OAAI
A call to action: improving access to cardiac MRI for diagnosis of immune checkpoint inhibitor related myocarditis in low and middle income countries

行动呼吁:改善低收入和中等收入国家免疫检查点抑制剂相关心肌炎诊断中的心脏MRI可及性

2025-10-310
OAAI